Kamran Shahid, MD
Hematology & Oncology · Lake Charles, LANPI 1336370642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,550 of the $154,780 with a category attached, or 79.8%. Merck accounts for 97.7% of it on its own, with 35 other manufacturers making up the rest. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $531.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$151K
- Novartis$508
- Genentech USA, Inc.$451
- Amgen$437
- AstraZeneca$269
- Johnson & Johnson$232
- plus $2K from 30 others
Across 14 payments — averaging $5034.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$37K
- Helsinn Healthcare SA$33K
What the payments were for
- Speaking & faculty fees$123,55080%
- Travel & lodging$24,46716%
- Food & beverage$6,5364%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 142 | $151,158 |
| Novartis | 29 | $508 |
| Genentech USA, Inc. | 13 | $451 |
| Amgen | 10 | $437 |
| AstraZeneca | 14 | $269 |
| Johnson & Johnson(3 entities) | 9 | $232 |
| Bristol Myers Squibb | 4 | $160 |
| Pfizer | 7 | $152 |
| GSK | 5 | $129 |
| Beigene USA, Inc. | 7 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $117 |
| Astellas Pharma US Inc | 6 | $105 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $99 |
| Puma Biotechnology, Inc. | 4 | $90 |
| Eisai Inc. | 4 | $89 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Incyte Corporation | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Exelixis Inc. | 2 | $42 |
| Gilead | 2 | $36 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Sobi, Inc | 1 | $28 |
| AbbVie | 1 | $27 |
| Taiho Oncology, Inc. | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Geron Corporation | 1 | $22 |
| Bayer | 1 | $19 |
| Sanofi | 1 | $18 |
| Beone Medicines USA, Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$154,780 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 26 | $328,057 |
| XtandiEnzalutamide | 17 | $175,543 |
| Abiraterone Acetate | 36 | $84,428 |
| Bicalutamide | 48 | $1,683 |
| Tamoxifen Citrate | 76 | $1,608 |
| Letrozole | 25 | $534 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $223 |
| Fluorouracil | 11 | $197 |
| Prednisone | 26 | $150 |
| Sodium Chloride0.9 % Sodium Chloride | 18 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $105 | $175,54317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Lake Charles
- Michael BergeronLake Charles$24K
- Leroy FredericksLake Charles$17K
- Michael BroussardLake Charles$17K
- Mohammad KhanLake Charles$11K
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.